Eventide Asset Management, LLC Freeline Therapeutics Holdings PLC Transaction History

Eventide Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.42 - $0.63 $511,612 - $767,418	-1,218,124 Reduced 20.57%	4,702,641 $2.16 Million
Q4 2022 Feb 13, 2023	SELL	$0.46 - $0.73 $13,448 - $21,341	-29,235 Reduced 0.49%	5,920,765 $2.84 Million
Q2 2022 Aug 15, 2022	BUY	$0.69 - $1.12 $1.62 Million - $2.63 Million	2,343,808 Added 64.99%	5,950,000 $5.17 Million
Q1 2022 May 16, 2022	BUY	$0.92 - $2.03 $110,893 - $244,688	120,536 Added 3.46%	3,606,192 $3.97 Million
Q3 2021 Nov 15, 2021	BUY	$3.04 - $8.9 $3.04 Million - $8.9 Million	1,000,000 Added 40.23%	3,485,656 $11.8 Million
Q4 2020 Feb 16, 2021	BUY	$14.94 - $18.3 $2.13 Million - $2.61 Million	142,352 Added 6.07%	2,485,656 $44.3 Million
Q3 2020 Nov 13, 2020	BUY	$15.45 - $18.12 $36.2 Million - $42.5 Million	2,343,304 New	2,343,304 $35.6 Million

30.1K

Ticker FRLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,972,300
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.